114 related articles for article (PubMed ID: 27186698)
1. Prognostic factors and treatment results of pediatric Hodgkin's lymphoma: A single center experience.
Büyükkapu-Bay S; Çorapçıoğlu F; Aksu G; Anık Y; Demir H; Erçin C
Turk J Pediatr; 2015; 57(4):359-66. PubMed ID: 27186698
[TBL] [Abstract][Full Text] [Related]
2. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
3. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
4. [Clinical analysis of childhood and adolescent Hodgkin's lymphoma: a report of 88 cases].
Xing PY; Shi YK; He XH; Zhou LQ; Dong M; Yang JL; Liu P
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):692-7. PubMed ID: 23159084
[TBL] [Abstract][Full Text] [Related]
5. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ;
J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968
[TBL] [Abstract][Full Text] [Related]
7. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.
Bonadonna G; Bonfante V; Viviani S; Di Russo A; Villani F; Valagussa P
J Clin Oncol; 2004 Jul; 22(14):2835-41. PubMed ID: 15199092
[TBL] [Abstract][Full Text] [Related]
8. Pediatric Hodgkin's disease.
Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
[TBL] [Abstract][Full Text] [Related]
9. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
[TBL] [Abstract][Full Text] [Related]
10. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up.
Brusamolino E; Baio A; Orlandi E; Arcaini L; Passamonti F; Griva V; Casagrande W; Pascutto C; Franchini P; Lazzarino M
Clin Cancer Res; 2006 Nov; 12(21):6487-93. PubMed ID: 17085663
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
Sasse S; Bröckelmann PJ; Goergen H; Plütschow A; Müller H; Kreissl S; Buerkle C; Borchmann S; Fuchs M; Borchmann P; Diehl V; Engert A
J Clin Oncol; 2017 Jun; 35(18):1999-2007. PubMed ID: 28418763
[TBL] [Abstract][Full Text] [Related]
12. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience.
Rose A; Grajales-Cruz A; Lim A; Todd A; Bello C; Shah B; Chavez J; Pinilla-Ibartz J; Saeed H; Sandoval-Sus J; Isenalumhe L; Sokol L
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):132-138. PubMed ID: 32950461
[TBL] [Abstract][Full Text] [Related]
13. Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
Weiner MA; Leventhal BG; Marcus R; Brecher M; Ternberg J; Behm FG; Cantor A; Wharam M; Chauvenet A
J Clin Oncol; 1991 Sep; 9(9):1591-8. PubMed ID: 1714950
[TBL] [Abstract][Full Text] [Related]
14. Consolidative radiation therapy for stage III Hodgkin lymphoma in patients who achieve complete response after ABVD chemotherapy.
Phan J; Mazloom A; Abboud M; Salehpour M; Reed V; Zreik T; Shihadeh F; Fisher C; Wogan C; Dabaja B
Am J Clin Oncol; 2011 Oct; 34(5):499-505. PubMed ID: 21537149
[TBL] [Abstract][Full Text] [Related]
15. Treatment results in advanced stage Hodgkin's lymphoma: a retrospective study.
Jain H; Sengar M; Nair R; Menon H; Laskar S; Shet T; Gujral S; Sridhar E
J Postgrad Med; 2015; 61(2):88-91. PubMed ID: 25766339
[TBL] [Abstract][Full Text] [Related]
16. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?
Laskar S; Gupta T; Vimal S; Muckaden MA; Saikia TK; Pai SK; Naresh KN; Dinshaw KA
J Clin Oncol; 2004 Jan; 22(1):62-8. PubMed ID: 14657226
[TBL] [Abstract][Full Text] [Related]
17. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
[TBL] [Abstract][Full Text] [Related]
18. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease.
Chronowski GM; Wilder RB; Tucker SL; Ha CS; Sarris AH; Hagemeister FB; Barista I; Hess MA; Cabanillas F; Cox JD
Cancer; 2002 Dec; 95(12):2534-8. PubMed ID: 12467067
[TBL] [Abstract][Full Text] [Related]
19. Hodgkin's disease in Indian children: outcome with chemotherapy alone.
Arya LS; Dinand V; Thavaraj V; Bakhshi S; Dawar R; Rath GK; Singh R; Vats TS
Pediatr Blood Cancer; 2006 Jan; 46(1):26-34. PubMed ID: 16161019
[TBL] [Abstract][Full Text] [Related]
20. [Our experiences in treating patients with Hodgkin disease in the last decade].
Simon Z; Keresztes K; Miltényi Z; Ress Z; Váróczy L; Vadász G; Gergely L; Illés A
Orv Hetil; 2007 Apr; 148(15):675-82. PubMed ID: 17416575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]